68 / 100

Dr. Orit Jacobson Weiss | Radiochemistry | Women Researcher Award

Dr. Orit Jacobson is a distinguished molecular imaging expert specializing in radiopharmaceutical development. Currently a Staff Scientist and Head of the Radiopharmaceutical Development Group at the Molecular Imaging Branch, NCI/NIH, she has over two decades of expertise in nuclear medicine, chemistry, and imaging. Her career spans significant leadership roles, including VP of R&D at Actithera, Inc., and groundbreaking contributions at NIH. With a prolific research portfolio and numerous patents, Dr. Jacobson is a recognized leader in radiopharmaceutical innovations and molecular imaging for oncology and theranostics.

Profile

Orcid

Scholar

🎓 Education

Postdoc (2008-2011): Laboratory of Molecular Imaging and Nanomedicine, NIH, USA. Ph.D. (2003-2008): Nuclear Medicine, Hadassah Hebrew University, Israel; Thesis on molecular imaging using PET. B.Sc. (1999-2002): Chemistry and Biology, Hebrew University, Israel. Dr. Jacobson’s academic journey emphasizes multidisciplinary excellence in chemistry, biology, and nuclear medicine.

💼 Experience 

NCI/NIH (2023-present): Staff Scientist, Head of Radiopharmaceutical Development. Actithera, Inc. (2021-2023): VP of R&D. NIBIB/NIH (2016-2021): Staff Scientist, Molecular Tracer Core Facility. Hadassah Hebrew University (2011-2013): Head of Chemistry/Radiochemistry Group. Dr. Jacobson’s career integrates leadership, innovation, and translational research.

🏆 Awards and Honors 

Travel Awards: WMIC (2015), ISRS (2009). Research Excellence: Fellows Award, NIH (2014). Academic Scholarships: Israel Academic Women Organization (2007).
Dr. Jacobson’s accolades reflect her outstanding contributions to molecular imaging and radiopharmaceutical sciences.

🔬 Research Focus

Dr. Jacobson’s work centers on radiopharmaceutical innovation, including CXCR4-targeted imaging, theranostics, and Evans Blue-based tracers. Her research advances oncology diagnostics, targeted radiotherapy, and translational imaging technologies, with a focus on improving cancer detection and treatment efficacy.

🏆Conclusion 

Dr. Jacobson is a distinguished researcher whose contributions to nuclear medicine and molecular imaging have advanced scientific knowledge and practical applications. Her expertise, leadership, and dedication to innovation make her an excellent candidate for the Women Researcher Award, celebrating her accomplishments and inspiring future generations of women scientists.

Publication:

  • Fluorine-18 radiochemistry, labeling strategies and synthetic routes
    Year: 2015
    Authors: O. Jacobson, D.O. Kiesewetter, X. Chen
    Citations: 588

 

  • Toxic reactive oxygen species enhanced synergistic combination therapy by self‐assembled metal‐phenolic network nanoparticles
    Year: 2018
    Authors: Y. Dai, Z. Yang, S. Cheng, Z. Wang, R. Zhang, G. Zhu, Z. Wang, B.C. Yung, et al.
    Citations: 380

 

  • Biomineralization-inspired synthesis of copper sulfide–ferritin nanocages as cancer theranostics
    Year: 2016
    Authors: Z. Wang, P. Huang, O. Jacobson, Z. Wang, Y. Liu, L. Lin, J. Lin, N. Lu, H. Zhang, et al.
    Citations: 379

 

  • Sequential drug release and enhanced photothermal and photoacoustic effect of hybrid reduced graphene oxide-loaded ultrasmall gold nanorod vesicles for cancer therapy
    Year: 2015
    Authors: J. Song, X. Yang, O. Jacobson, L. Lin, P. Huang, G. Niu, Q. Ma, X. Chen
    Citations: 369

 

  • Ultrasmall Gold Nanorod Vesicles with Enhanced Tumor Accumulation and Fast Excretion from the Body for Cancer Therapy
    Year: 2015
    Authors: J. Song, X. Yang, O. Jacobson, P. Huang, X. Sun, L. Lin, X. Yan, G. Niu, Q. Ma, et al.
    Citations: 304

 

  • Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy
    Year: 2017
    Authors: G. Zhu, G.M. Lynn, O. Jacobson, K. Chen, Y. Liu, H. Zhang, Y. Ma, F. Zhang, et al.
    Citations: 301

 

  • Tumor‐specific drug release and reactive oxygen species generation for cancer chemo/chemodynamic combination therapy
    Year: 2019
    Authors: S. Wang, Z. Wang, G. Yu, Z. Zhou, O. Jacobson, Y. Liu, Y. Ma, F. Zhang, et al.
    Citations: 279

 

  • Supramolecular polymer-based nanomedicine: high therapeutic performance and negligible long-term immunotoxicity
    Year: 2018
    Authors: G. Yu, X. Zhao, J. Zhou, Z. Mao, X. Huang, Z. Wang, B. Hua, Y. Liu, F. Zhang, et al.
    Citations: 257

 

  • Enhanced antitumor efficacy by a cascade of reactive oxygen species generation and drug release
    Year: 2019
    Authors: S. Wang, G. Yu, Z. Wang, O. Jacobson, L.S. Lin, W. Yang, H. Deng, Z. He, Y. Liu, et al.
    Citations: 252

 

  • Intertwining DNA-RNA nanocapsules loaded with tumor neoantigens as synergistic nanovaccines for cancer immunotherapy
    Year: 2017
    Authors: G. Zhu, L. Mei, H.D. Vishwasrao, O. Jacobson, Z. Wang, Y. Liu, B.C. Yung, X. Fu, et al.
    Citations: 238

 

Orit Jacobson Weiss | Radiochemistry | Women Researcher Award

You May Also Like